These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 8603941)

  • 21. Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.
    Baxter R; Keshavan P; Welsch JA; Han L; Smolenov I
    Hum Vaccin Immunother; 2016 May; 12(5):1300-10. PubMed ID: 26829877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opsonophagocytosis of fluorescent polystyrene beads coupled to Neisseria meningitidis serogroup A, C, Y, or W135 polysaccharide correlates with serum bactericidal activity.
    Martinez J; Pilishvili T; Barnard S; Caba J; Spear W; Romero-Steiner S; Carlone GM
    Clin Diagn Lab Immunol; 2002 Mar; 9(2):485-8. PubMed ID: 11874898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation.
    Fusco PC; Farley EK; Huang CH; Moore S; Michon F
    Clin Vaccine Immunol; 2007 May; 14(5):577-84. PubMed ID: 17376859
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years.
    McVernon J; MacLennan J; Pollard AJ; Oster P; Wakefield MJ; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2003 Jul; 22(7):659-61. PubMed ID: 12886896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
    Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
    Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meningococcal surrogates of protection--serum bactericidal antibody activity.
    Borrow R; Balmer P; Miller E
    Vaccine; 2005 Mar; 23(17-18):2222-7. PubMed ID: 15755600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and characterization of anti-idiotype based peptide and DNA vaccines which mimic the capsular polysaccharide of Neisseria meningitidis serogroup C.
    Westerink MA; Smithson SL; Hutchins WA; Widera G
    Int Rev Immunol; 2001; 20(2):251-61. PubMed ID: 11878768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-Propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis.
    Pon RA; Lussier M; Yang QL; Jennings HJ
    J Exp Med; 1997 Jun; 185(11):1929-38. PubMed ID: 9166422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outer membrane vesicles extracted from Neisseria meningitidis serogroup X for prevention of meningococcal disease in Africa.
    Acevedo R; Zayas C; Norheim G; Fernández S; Cedré B; Aranguren Y; Cuello M; Rodriguez Y; González H; Mandiarote A; Pérez M; Hernández M; Hernández-Cedeño M; González D; Brorson SH; Rosenqvist E; Naess L; Tunheim G; Cardoso D; García L
    Pharmacol Res; 2017 Jul; 121():194-201. PubMed ID: 28495657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005.
    Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V
    Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects for vaccine prevention of meningococcal infection.
    Harrison LH
    Clin Microbiol Rev; 2006 Jan; 19(1):142-64. PubMed ID: 16418528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants.
    Fairley CK; Begg N; Borrow R; Fox AJ; Jones DM; Cartwright K
    J Infect Dis; 1996 Dec; 174(6):1360-3. PubMed ID: 8940235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of serum bactericidal antibody and opsonic antibody levels after Neisseria meningitidis serogroup C conjugate vaccine in Brazilian children and adolescents infected or not infected with HIV.
    Pereira-Manfro WF; Alvino RM; Cruz AC; Silva GP; Castro RB; Ferreira B; Barreto DM; Frota AC; Hofer CB; Milagres LG
    Vaccine; 2016 Dec; 34(50):6116-6119. PubMed ID: 27847176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.
    Platonov AE; Beloborodov VB; Pavlova LI; Vershinina IV; Käyhty H
    Clin Exp Immunol; 1995 Apr; 100(1):32-9. PubMed ID: 7697919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production of low-avidity antibody by infants after infection with serogroup B meningococci.
    Pollard AJ; Levin M
    Lancet; 2000 Dec; 356(9247):2065-6. PubMed ID: 11145494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review of meningococcal vaccines with emphasis on possible immunoprophylaxis of group B disease.
    Frøholm LO
    NIPH Ann; 1980 Dec; 3(2):67-74. PubMed ID: 6784045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.